Mark Neumann Intra Cellular Therapies, Inc. (ITCI) insider trading activity

Mark Neumann is EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 29,700 shares of ITCI, which is worth approximately $2.71 Million. The most recent transaction as insider was on Aug 16, 2024, when has been sold 18,714 shares (Common Stock) at a price of $75.08 per share, resulting in proceeds of $1,405,047. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.7K

0% 3M change

0% 12M change

Total Value Held $2.71 Million

Mark Neumann Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 16 2024	SELL Open market or private sale	$1,405,047 $75.08 p/Share	18,714 Reduced 38.65%	29,700 Common Stock
Aug 16 2024	BUY Exercise of conversion of derivative security	$690,359 $36.89 p/Share	18,714 Added 27.88%	48,414 Common Stock
Mar 11 2024	SELL Open market or private sale	$484,476 $65.96 p/Share	7,345 Reduced 19.83%	29,700 Common Stock
Mar 10 2024	BUY Exercise of conversion of derivative security	-	7,345 Added 16.55%	37,045 Common Stock
Mar 07 2024	SELL Open market or private sale	$875,379 $66.66 p/Share	13,132 Reduced 30.66%	29,700 Common Stock
Mar 06 2024	BUY Exercise of conversion of derivative security	-	13,132 Added 23.47%	42,832 Common Stock
Feb 26 2024	SELL Open market or private sale	$552,462 $69.87 p/Share	7,907 Reduced 21.03%	29,700 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	7,907 Added 17.37%	37,607 Common Stock
Feb 02 2024	SELL Open market or private sale	$795,568 $67.08 p/Share	11,860 Reduced 28.54%	29,700 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	11,860 Added 22.2%	41,560 Common Stock
Nov 06 2023	SELL Open market or private sale	$2,352,811 $55.5 p/Share	42,393 Reduced 58.8%	29,700 Common Stock
Nov 06 2023	BUY Exercise of conversion of derivative security	$640,490 $23.94 p/Share	26,754 Added 27.07%	72,093 Common Stock
Aug 07 2023	SELL Open market or private sale	$3,251,087 $58.79 p/Share	55,300 Reduced 54.95%	45,339 Common Stock
Aug 07 2023	BUY Exercise of conversion of derivative security	$1,028,027 $18.59 p/Share	55,300 Added 35.46%	100,639 Common Stock
Mar 28 2023	SELL Open market or private sale	$849,325 $54.43 p/Share	15,604 Reduced 25.6%	45,339 Common Stock
Mar 13 2023	SELL Open market or private sale	$167,494 $44.57 p/Share	3,758 Reduced 5.81%	60,943 Common Stock
Mar 10 2023	SELL Open market or private sale	$368,676 $43.12 p/Share	8,550 Reduced 12.97%	57,357 Common Stock
Mar 10 2023	BUY Exercise of conversion of derivative security	-	7,344 Added 10.19%	64,701 Common Stock
Mar 09 2023	BUY Grant, award, or other acquisition	-	16,708 Added 20.22%	65,907 Common Stock
Mar 01 2023	SELL Open market or private sale	$362,122 $50.01 p/Share	7,241 Reduced 12.83%	49,199 Common Stock
Feb 24 2023	SELL Open market or private sale	$190,647 $47.12 p/Share	4,046 Reduced 6.69%	56,440 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	-	7,906 Added 11.56%	60,486 Common Stock
Feb 21 2023	SELL Open market or private sale	$185,622 $47.62 p/Share	3,898 Reduced 6.9%	52,580 Common Stock
Feb 18 2023	BUY Exercise of conversion of derivative security	-	11,139 Added 16.47%	56,478 Common Stock
Apr 08 2022	SELL Open market or private sale	$5,558,221 $64.37 p/Share	86,348 Reduced 65.57%	45,339 Common Stock

Mark Neumann

EVP, Chief Commercial Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Value

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI

Account